PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.811
EU - Europa 10.702
AS - Asia 3.658
AF - Africa 73
SA - Sud America 69
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 21
Totale 30.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.724
IT - Italia 3.356
IE - Irlanda 2.160
GB - Regno Unito 1.869
CN - Cina 1.096
SG - Singapore 940
SE - Svezia 938
DE - Germania 818
HK - Hong Kong 581
UA - Ucraina 345
FI - Finlandia 241
FR - Francia 225
ID - Indonesia 216
TR - Turchia 215
RU - Federazione Russa 191
BG - Bulgaria 165
IN - India 157
VN - Vietnam 119
CA - Canada 77
JP - Giappone 67
LT - Lituania 60
TW - Taiwan 58
BE - Belgio 57
NL - Olanda 51
AU - Australia 45
MY - Malesia 39
ES - Italia 37
IQ - Iraq 36
IR - Iran 35
CZ - Repubblica Ceca 33
BR - Brasile 32
EG - Egitto 32
KR - Corea 30
CH - Svizzera 22
PL - Polonia 22
RO - Romania 18
EU - Europa 17
CL - Cile 14
PK - Pakistan 13
AL - Albania 12
PH - Filippine 12
AR - Argentina 11
GR - Grecia 11
DK - Danimarca 8
ET - Etiopia 8
MK - Macedonia 8
NG - Nigeria 8
SI - Slovenia 8
HU - Ungheria 7
TH - Thailandia 7
MT - Malta 6
MX - Messico 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
GH - Ghana 5
IL - Israele 5
LV - Lettonia 5
BD - Bangladesh 4
CO - Colombia 4
KE - Kenya 4
NO - Norvegia 4
SA - Arabia Saudita 4
SY - Repubblica araba siriana 4
TZ - Tanzania 4
AP - ???statistics.table.value.countryCode.AP??? 3
AT - Austria 3
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
EC - Ecuador 3
HR - Croazia 3
IS - Islanda 3
KH - Cambogia 3
MA - Marocco 3
NZ - Nuova Zelanda 3
ZA - Sudafrica 3
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MD - Moldavia 2
RS - Serbia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
IM - Isola di Man 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MC - Monaco 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MZ - Mozambico 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
ZM - Zambia 1
Totale 30.382
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.283
Dublin 2.155
Fairfield 1.752
Chandler 1.433
Southend 1.325
Ashburn 1.123
Woodbridge 1.011
Houston 760
Singapore 749
Dearborn 735
Seattle 704
Nyköping 668
Ann Arbor 666
Jacksonville 601
Wilmington 601
Hong Kong 554
Cambridge 535
Beijing 318
Modena 278
Milan 277
New York 266
Jakarta 212
Rome 191
San Diego 178
Helsinki 175
Princeton 174
Sofia 164
Eugene 141
Izmir 129
Bologna 128
Shanghai 121
Dong Ket 112
Fremont 104
Redwood City 104
London 86
Moscow 84
Bremen 77
Falls Church 67
Munich 65
Naples 51
Brussels 47
Guangzhou 46
Turin 46
Parma 44
Norwalk 43
Reggio Emilia 43
Boardman 40
Bari 37
Genoa 35
San Giuliano Milanese 35
Los Angeles 34
Florence 33
Frankfurt am Main 33
Ottawa 33
Enfield 32
Nanjing 31
Palermo 31
Des Moines 30
Phoenix 30
Padova 28
Hefei 27
Paris 24
Catania 23
Tokyo 23
Baghdad 22
Lansdale 22
Pisa 22
Asyut 21
Brno 21
Kunming 21
San Mateo 21
Vicenza 20
Toronto 19
Dallas 18
Mumbai 18
Verona 18
Amsterdam 17
Chicago 16
Wuhan 16
Fulham 15
Sassuolo 15
Taipei 15
Banqiao 14
Brescia 14
Brooklyn 14
Chiswick 14
Absecon 13
Hyderabad 13
Trieste 13
Nanchang 12
Napoli 12
Perugia 12
Rimini 12
Bangalore 11
Madrid 11
New Taipei 11
Sydney 11
Falkenstein 10
Jinan 10
Monza 10
Totale 22.539
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 765
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 418
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 340
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 328
GD2 expression in breast cancer. 314
Abemaciclib: eventi avversi e riduzione di dose. 313
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 305
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 304
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 303
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 287
Oxford Manuale di Medicina Clinica 282
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 281
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 274
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 270
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 268
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 264
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 260
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 258
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. 254
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 247
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 242
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 241
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 240
Tumor Stroma Manipulation By MSC 236
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 233
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 232
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 232
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 231
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 229
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 226
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 224
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 223
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 218
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 217
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 216
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 215
Immune characterization of breast cancer metastases: prognostic implications. 214
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 214
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 214
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 210
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 208
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 207
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 206
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 206
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 205
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 205
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 205
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 205
Achievements and unmet needs in the management of advanced ovarian cancer 204
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 204
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 204
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 204
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 201
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 200
Prognostic Factors for Breast Cancer: an Immunomorphological Update 198
Timing for starting second line therapy in recurrent ovarian cancer. 198
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 195
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 194
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 192
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 191
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 190
Breast Location for De Novo Extramedullary Myeloid Sarcoma 189
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 189
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 186
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 185
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 184
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 182
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 182
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 179
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 174
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 174
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 172
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 171
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 170
Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: biomarker analyses of the randomized phase II LET-LOB study 168
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 168
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 167
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 166
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 165
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 164
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 163
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 162
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 160
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 160
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 160
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 159
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 158
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 157
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 157
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 155
Lapatinib and renal impairment: a case report 154
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 152
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 148
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 148
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 147
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 147
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 147
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 147
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. 146
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 145
Totale 21.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.319
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.319
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.888 0 0 0 0 0 685 831 386 385 178 273 150
2020/20214.274 426 201 259 330 484 369 364 456 266 465 345 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20254.905 357 209 270 727 1.882 1.460 0 0 0 0 0 0
Totale 30.751